We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Die Studie erreichte ihr Ziel beim primären Endpunkt, der Senkung des Nüchternblutzuckers – Risikofaktor für Typ-2-Diabetes, bei einer Tagesdosis von 5 g und drei Verabreichungen pro Tag mit...
The study achieved its objective on the primary endpoint, the reduction of fasting blood glucose, a risk factor for type 2 diabetes, at a 5g daily dose in 3 intakes per day, with a high...
Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating...
Regulatory News: Valbiotis (FR0013254851 – ALVAL, éligible PEA / PME) (Paris:ALVAL), entreprise de Recherche et Développement à dimension commerciale, engagée dans l’innovation scientifique, pour...
Regulatory News: Valbiotis (FR0013254851 – ALVAL, éligible PEA / PME) (Paris:ALVAL), entreprise de Recherche et Développement à dimension commerciale, engagée dans l’innovation scientifique, pour...
Eine Barposition von mehr als 20 Millionen Euro zum Ende 2022, die dem Unternehmen finanzielle Visibilität bis zum Ende des ersten Halbjahres 2024 verschafft Ein entscheidendes Jahr an der...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.014 | -1.00286532951 | 1.396 | 1.398 | 1.334 | 41255 | 1.36064914 | DE |
4 | 0.112 | 8.8188976378 | 1.27 | 1.52 | 1.212 | 111156 | 1.37046459 | DE |
12 | 0.152 | 12.3577235772 | 1.23 | 1.52 | 1.15 | 92500 | 1.32934192 | DE |
26 | 0.218 | 18.7285223368 | 1.164 | 1.9 | 1.08 | 95026 | 1.4147613 | DE |
52 | -3.278 | -70.3433476395 | 4.66 | 5.3 | 1.07 | 85457 | 2.01000058 | DE |
156 | -5.478 | -79.8542274052 | 6.86 | 7.5 | 1.07 | 44966 | 3.17832411 | DE |
260 | -0.778 | -36.0185185185 | 2.16 | 8.38 | 1.07 | 35127 | 3.61764132 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions